echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > IkT-148009 treats Parkinson's, phase I clinical trials have officially begun

    IkT-148009 treats Parkinson's, phase I clinical trials have officially begun

    • Last Update: 2021-02-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical company Inhibikase Therapeutics announced today that its Phase I clinical trial of IkT-148009 to treat Parkinson's has officially begun.
    IkT-148009 is an Abelson non-subject tyrosine kinase (c-Abl) inhibitor used to treat Parkinson's.
    Abelson non-subject tyrosine kinase (c-Abl) has been linked to nerve spots and neurogenic fiber entanglements in the brains of patients with Alzheimer's disease and other neurodegenerative diseases.
    random Phase I study is exploring the safety, toerability, and pharmacodynamics (PK) of IkT-148009 in healthy volunteers ages 45 to 70, with the aim of determining the maximum to-dosage and PK curve of IkT-148009.
    in preclinical animal models, the company demonstrated that daily oral treatment with IkT-148009 can prevent and reverse the loss of function in the brain and gastrointestinal tract.
    , Chief Executive Officer of Inhibikase Therapeutics, said: "The launch of the Phase I study on the treatment of Parkinson's disease by IkT-148009 represents an important milestone for Inhibik Therapeutics.
    Based on preclinical data, we believe that c-Abl plays an important role in the onset of Parkinson's disease, so inhibiting c-Abl represents a promising therapy."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.